Under the terms of the agreement, JTGD has the exclusive rights to distribute RPC’s Onko-Sure in vitro diagnostic cancer test in India and will be responsible for product sales, marketing and government regulatory in the territory.

Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).

Onko-Sure is approved by the FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and cancer monitoring tool.

JTGD anticipates receiving Indian government support in various regions to implement the Onko-Sure cancer test as a cancer screening tool for populations at risk.

Radient claimed that this will be the first large scale Onko-Sure cancer testing/screening initiative. JTGD has initiated Onko-Sure cancer testing in hospitals and cancer clinics throughout India. The agreement is RPC’s cornerstone and guide for developing a broader government backed health-care strategy to encourage widespread screening of population sat cancer risk.

Umesh Bhatia, CEO of JTGD, said: “Onko-Sure is being well accepted by the Indian Medical community. We’ve already seen the impact that Onko-Sure is making in saving patient lives. Onko-Sure, when used as a general screen, was able to identify early-stage cancers that were otherwise missed by standard tests. We expect Onko-Sure will become the leading cancer test and early screening tool in India.”

Douglas MacLellan, chairman and CEO of RPC, said: “This new distribution agreement with JTGD provides Radient Pharmaceuticals with a path for the first large scale use of the Onko-Sure cancer test as a general cancer screening tool.

“This initial general cancer screening program is the first step in moving Onko-Sure into becoming a generally accepted cancer screening tool throughout critical healthcare markets where such diagnostics will have a positive effect on patient care.”